Mikrobiomem Mediatorowane Metabolity Flawonoidów dla Zdrowia Kognitywnego (MAEVE)
MAEVE: Metabolity Flawonoidowe Mediatorowane przez Mikrobiotę dla Zdrowia Poznawczego
Globally, populations are ageing increasing the prevalence of Alzheimer's disease (AD), due to lack of effective treatments. The traditional Mediterranean diet, rich in fibre and polyphenols (PPs) can help prevent or delay cognitive dysfunction and preserve healthy brain structure and function. Cognitive decline is inversely associated with higher PP intakes (>421mg/day) i.e., total flavonoids, flavan-3-ols and flavonoid oligomers. The positive brain effects of flavonoid intake are likely mediated in part by gut microbial PP metabolites, consistent with the emerging role of the brain-gut microbiome (BGM) system in neurodegeneration. Our preliminary data indicate that circulating phenyl-γ-valerolactones (PVL), neuroprotective compounds exclusively produced by gut microbiota from flavan-3-ol rich foods18 are associated with delaying cognitive dysfunction. Intake of PPs change gut microbial composition and function, altering the physiology of the host's secondary bile acid (BA) pool through modulation of bacterial 7α-dehydroxylation of de-conjugated primary BAs into secondary BAs. This is noteworthy as 7α-dehydroxylation of BAs does not happen in the brain and because gut microbial BA metabolites have regulatory and signalling functions in the brain. The ratio between certain primary and secondary BAs is also dysregulated in AD with significantly lower serum concentrations of cholic acid (a primary BA) and increased levels of deoxycholic acid (a bacterially produced secondary BA). The increased ratio of cholic acid to deoxycholic acid is correlated with cognitive decline. Increased levels of tyrosine, tryptophan, purine, and tocopherol have also been identified in postmortem AD brains. However, specific pathways and mechanisms underlying these associations are unclear. In this multi-PI application by leaders in the field of BGM interactions, we leverage the collectively (NIH, HSC, SFI) funded Tripartite US-Ireland R&D Partnership Program to determine the mechanisms involved in PP intake on maintaining healthier cognitive and brain function, as mediated by gut microbiota metabolites of PP and BAs in 50+ year old elderly with enhanced AD risk.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Chris Gill, PhD
- Numer telefonu: +44 28 7012 3181
- E-mail: c.gill@ulster.ac.uk
Kopia zapasowa kontaktu do badania
- Nazwa: Aoife Caffrey, PhD
- Numer telefonu: +44 (0) 28 701 23401
- E-mail: a.caffrey@ulster.ac.uk
Lokalizacje studiów
-
-
-
Coleraine, Zjednoczone Królestwo, BT52 1SA
- Rekrutacyjny
- Ulster University, Human Intervention Studies Unit
-
Kontakt:
- Aoife Caffrey, PhD
- Numer telefonu: +44 (0) 28 701 23401
- E-mail: a.caffrey@ulster.ac.uk
-
Kontakt:
- E-mail: c.gill@ulster.ac.uk
-
Główny śledczy:
- Chris Gill, PhD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- 50+ years
- BMI ≥ 25 kg/m2
- Enhanced risk of AD - defined as family history of AD, 1st degree family member
- Habitually consume suboptimal diets such as typical Western diet (i.e., high in animal products, refined carbohydrates and processed food).
- Subjects capable of and willing to comply with the protocol and to give their written informed consent.
Exclusion Criteria:
- Cognitive impairment at time of recruitment into the study, as measured by the Mini Mental Status Exam (MMSE, score 25-30), and Clinical Dementia Rating (CDR, score=0) or Everyday Cognition Scale-12 (ECog-12, score<1.36 included).
- Pre-existing psychosis or psychiatric conditions.
- Currently receiving treatment for dementia.
- History of substance abuse or cerebrovascular events.
- Heavy use of tobacco (>1/2 pack per day)
- Any intolerance or allergy documented or suspected to one of the components of the study products.
- Have taken probiotics or antibiotic therapy within the last 1 month
- Change in medication use in the last 3 months.
- Frailty, malnutrition, or food allergy/intolerance requiring special diets will also be excluded.
- Following any specific diet (vegetarian, vegan, etc.)
- Body weight at enrolment greater than 400lbs due to weight restrictions on the MRI table.
- Pregnant, breastfeeding, postpartum for less than 6 months, or unwilling to practice birth control during participation in the study.
- Unable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, or metallic foreign body, etc.)
- Chronic pain.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
- Having a psychological or linguistic inability to sign the informed consent;
- Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
- Subject participating in another biomedical study or participation in another study within the 3 months before entry into this study.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Komparator placebo: Suplement placebo
|
Micronutrient matched placebo |
|
Eksperymentalny: Polyphenol Supplement
Juice Plus Essentials, Berry Blend Capsules |
Juice Plus Essentials, Berry Blend Capsules |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Differences in Polyphenol-derived metabolite concentrations pre, mid, & post intervention - stool
Ramy czasowe: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (month 6), and once at the final 12month appointment (month 12)
|
Measurement of metabolomics via stool specimen. |
Collected three times by the participant at home, once at baseline (week 0), once at mid-study (month 6), and once at the final 12month appointment (month 12)
|
|
Differences in Polyphenol-derived metabolite concentrations pre, mid, & post intervention - blood
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Measurement of metabolomics via blood specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in microbiome levels pre, mid, & post intervention - Stool
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
16S RNA sequencing to measure microbiome levels via stool specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in microbiome levels pre & post intervention - Blood
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
16S RNA sequencing to measure microbiome levels via blood specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in microbiome levels pre, mid, & post intervention - Stool
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in microbiome levels pre, mid, & post intervention - Blood
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Cognitive Measures pre, mid, & post intervention - Executive Function
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Administration of a standardized Stroop Neuro-psychological test; participants ability to correctly identify colours when words are printed in conflicting ink colours. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Cognitive Measures pre, mid, & post intervention - Executive Function
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Administration of a standardized Trails A & B; participants ability to connect dots, in order, as quickly as possible. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Cognitive Measures pre, mid, & post intervention
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Cognitive Measures pre, mid, & post intervention
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Administration of a standardized arithmetic task; participants ability to complete quick mental math. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Differences in tryptophan-associated metabolite profiles pre, mid, and post intervention - Stool
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Measurement of tryptophan-associate metabolite profiles via stool specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Bile Acid's (BA's) pre, mid, & post intervention - Stool
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Measurement of BA's via stool specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Inflammatory markers pre, mid, & post intervention - Blood
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Measurement of inflammatory markers via blood specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Differences in Alzheimer's Disease (AD) markers pre, mid, & post intervention - Blood [Time
Ramy czasowe: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
Measurement of AD markers via blood specimen. |
Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
|
|
Anthropometrics - BMI
Ramy czasowe: Measured three times, once at each in-clinic appointment (week 0, month 6, month 12)
|
Measurement of height(in) and weight(lbs), used to calculate body mass index (BMI) |
Measured three times, once at each in-clinic appointment (week 0, month 6, month 12)
|
|
Questionnaire Data
Ramy czasowe: Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.
|
Use of validated surveys to assess ingestive behaviours, social isolation, stress, health, physical activity, etc., self-reported by the participant at home. |
Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.
|
|
Monthly Questionnaire Data
Ramy czasowe: Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.
|
Collected once a month for the duration of the study (12months). |
Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.
|
|
Anthropometrics - waist and hip circumference
Ramy czasowe: Measured three times, once at each in-clinic appointment (week 0, month 6, & month 12)
|
Measurement of waist and hip circumference (cm) |
Measured three times, once at each in-clinic appointment (week 0, month 6, & month 12)
|
|
Systolic and Diastolic Blood Pressure
Ramy czasowe: Measured three times, once at each in-clinic appointment (week 0, month 6, month 12).
|
Measurement of the pressure of circulating blood at rest |
Measured three times, once at each in-clinic appointment (week 0, month 6, month 12).
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Differences in Multimodal Brain Signatures pre, mid, & post intervention
Ramy czasowe: Measured thrice, once at baseline (week 0), mid-study (month 6), and final 12month appointment (month 12) visit.
|
Neuroimaging of participants brain via magnetic resonance imaging (MRI) procedure. |
Measured thrice, once at baseline (week 0), mid-study (month 6), and final 12month appointment (month 12) visit.
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Chris Gill, PhD, Ulster University, Human Intervention Studies Unit, Coleraine, Co. Londonderry, BT52 1SA, United Kingdom.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- REC/25/0046
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .